Better Days Ahead for the Plastic Industry
The Government of India (GoI) has revised the guidelines on the Credit Linked Capital Subsidy Scheme (CLCSS) in a bid to enable the small-scale pharma units to avail the benefits of the scheme.
The second supplement of the revised guidelines on the CLCSS scheme has been issued by the Development Commissioner for MSME of the Ministry of MSMEs. The scheme is expected to encourage the technological upgradation of micro and small enterprises.
'The SSI pharma sector is expected to be hugely benefited by the revised guidelines on the CLCSS scheme as it will help them adopt new technologies, which is required to comply with the manufacturing standards,' said Sangeet Kumar, Proprietor and Head of a healthcare centre in Ranchi, Modern Diagnostics.
The revised guidelines include a list of 179 machineries and equipments recommended for drugs and Pharmaceuticals Chemicals Products, including the existing technologies in the CLCSS required for Schedule M compliance.
Under this scheme, a total amount of Rs 400 crore could be availed by the SSI pharma sector to enhance their product line. Over 3,000 SSI pharma units are expected to be benefited from the revised scheme.
For more detail on B2b log on to http://www.bizxchange.in/
The Government of India (GoI) has revised the guidelines on the Credit Linked Capital Subsidy Scheme (CLCSS) in a bid to enable the small-scale pharma units to avail the benefits of the scheme.
The second supplement of the revised guidelines on the CLCSS scheme has been issued by the Development Commissioner for MSME of the Ministry of MSMEs. The scheme is expected to encourage the technological upgradation of micro and small enterprises.
